Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Dec 04, 2025, 17:31 ET

      Share this article

      Share this article


      The basal cell carcinoma market is anticipated to experience a positive shift due to the better uptake of existing drugs, the expected market launch of new therapies such as Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), and others, and increased awareness.

      LAS VEGAS, Dec. 4, 2025 /PRNewswire/ -- DelveInsight's Basal Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, basal cell carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). 

      Basal Cell Carcinoma Market Summary

      • The market size for basal cell carcinoma in the leading markets is expected to grow significantly by 2034.
      • The United States accounted for the highest basal cell carcinoma treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
      • BCC is the most common form of skin cancer. An estimated 3.6 million cases of BCC are diagnosed in the US each year.
      • Leading basal cell carcinoma companies developing emerging therapies, such as Medvir, Sirnaomics, Stamford Pharmaceuticals, Lytix Biopharma, Verrica Pharmaceuticals, and others, are developing new therapy for basal cell carcinoma that can be available in the basal cell carcinoma market in the coming years. 
      • The promising basal cell carcinoma therapies in clinical trials include Remetinostat, STP705, SP-002, LTX-315/VP-315, and others.

      Discover the basal cell carcinoma new treatment @ New Treatments for Basal Cell Carcinoma

      Key Factors Driving the Growth of the Basal Cell Carcinoma Market 

      Rising Incidence and Aging Population

      The global incidence of basal cell carcinoma is increasing due to prolonged exposure to ultraviolet (UV) radiation, genetic predispositions, and an aging population that is more susceptible to skin cancers. As people live longer and spend more time outdoors, the number of diagnosed cases continues to rise, fueling demand for effective treatments.

      Technological Advancements and Treatment Innovations

      Recent years have seen significant progress in BCC treatment modalities, including targeted therapies (such as hedgehog pathway inhibitors like vismodegib and sonidegib), immunotherapies, and personalized medicine approaches. Minimally invasive options, such as intralesional injections and topical treatments, are gaining popularity due to their reduced side effects and improved patient outcomes. The integration of artificial intelligence (AI) and digital health solutions is also enhancing early diagnosis and treatment planning.

      Launch of Emerging BCC Drugs 

      The expected launch of therapies such as Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), and others will change the dynamics of the BCC market.

      Basal Cell Carcinoma Market Analysis

      Current treatment options for basal cell carcinoma include topical medications such as 5-fluorouracil and imiquimod, photodynamic therapy using methyl aminolevulinate cream, tazarotene, hedgehog pathway inhibitors (HHPIs), and the PD-1 inhibitor cemiplimab.

      The U.S. FDA has approved several therapies for advanced BCC, including cemiplimab (LIBTAYO, by Regeneron Pharmaceuticals and Sanofi), vismodegib (ERIVEDGE, by Genentech), and sonidegib (ODOMZO, by Novartis), among others.

      Notable emerging players developing novel BCC treatments include Medvir (remetinostat), Sirnaomics (STP705), Stamford Pharmaceuticals (SP-002), and Lytix Biopharma/Verrica Pharmaceuticals (LTX-315/VP-315), all contributing to a promising pipeline of future therapeutic options.

      To know more about basal cell carcinoma treatment options, visit @ Approved Basal Cell Carcinoma Drugs

      Basal Cell Carcinoma Competitive Landscape

      Some of the BCC drugs in clinical trials include Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), and others.

      Lytix Biopharma/Verrica Pharmaceuticals' LTX-315 is an oncolytic peptide designed for direct injection into tumors. It destroys cancer cells while activating the immune system to enhance antitumor activity. Preclinical data demonstrate its ability to suppress tumor growth, trigger regression, and establish long-term immune protection. Verrica Pharmaceuticals has licensed LTX-315, a first-in-class oncolytic peptide immunotherapy, from Lytix Biopharma AS for use in dermatologic oncology. The U.S. patents for LTX-315 are expected to expire between 2032 and 2045.

      Stamford Pharmaceuticals' SP-002 is an adenovirus-based biologic engineered to express Interferon-g, an immunostimulatory protein with anticancer properties. Stamford Pharmaceuticals holds an exclusive global license to develop SP-002 (formerly TG1042) from Transgene, a French biopharmaceutical company. A Phase IIb trial for locally advanced basal cell carcinoma (laBCC) is currently underway, with Phase III studies in BCC expected to commence in late 2025 or early 2026.

      Sirnaomics' STP705 is a dual inhibitor targeting TGF-ß1 and COX-2, two key molecular drivers in oncology and fibrosis. By downregulating these genes, STP705 aims to suppress tumor growth and potentially offer a non-surgical treatment option for BCC. Recent Phase II results have shown remarkable efficacy with no drug-related or serious adverse events, reinforcing the candidate's strong potential in treating non-melanoma skin cancers and other indications.

      The anticipated launch of these emerging therapies are poised to transform the basal cell carcinoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the basal cell carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about therapy for basal cell carcinoma @ Basal Cell Carcinoma Clinical Trials 

      What is Basal Cell Carcinoma?

      Basal cell carcinoma (BCC), formerly known as basal cell epithelioma, is the most common form of skin cancer. It generally grows slowly, and metastasis occurs only in rare cases. BCC usually stays confined to the skin, and surgical interventions are the primary and most effective treatment approaches. Common procedures include surgical excision, electrodesiccation with curettage, and Mohs micrographic surgery, all offering high cure rates depending on the tumor's type and site.

      Basal Cell Carcinoma Epidemiology Segmentation

      The basal cell carcinoma epidemiology section provides insights into the historical and current basal cell carcinoma patient pool and forecasted trends for the leading markets. BCC is more common in the male population compared to females, attributed to greater sun exposure among men.

      The basal cell carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

      • Total Incident Cases of Non-Melanoma Skin Cancer
      • Total Incident Cases of BCC
      • Subtype-specific Incident Cases of BCC
      • Stage-specific Incident Cases of BCC
      • Line-wise Treated Cases of BCC

      Basal Cell Carcinoma Market Report Metrics

      Details

      Study Period

      2020–2034

      Basal Cell Carcinoma Market Report Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Basal Cell Carcinoma Epidemiology Segmentation

      Total Incident Cases of Non-Melanoma Skin Cancer, Total Incident Cases of BCC, Subtype-specific Incident Cases of BCC, Stage-specific Incident Cases of BCC, and Line-wise Treated Cases of BCC

      Key Basal Cell Carcinoma Companies

      Medvir, Sirnaomics, Stamford Pharmaceuticals, Lytix Biopharma, Verrica Pharmaceuticals, Regeneron, Sanofi, Novartis, Genentech, and others

      Key Basal Cell Carcinoma Therapies

      Remetinostat, STP705, SP-002, LTX-315/VP-315, LIBTAYO, ODOMZO, ERIVEDGE, and others

      Scope of the Basal Cell Carcinoma Market Report

      • Therapeutic Assessment: Basal Cell Carcinoma current marketed and emerging therapies
      • Basal Cell Carcinoma Market Dynamics: Key Market Forecast Assumptions of Emerging Basal Cell Carcinoma Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Basal Cell Carcinoma Market Access and Reimbursement

      Download the report to understand which factors are driving basal cell carcinoma therapeutics market trends @ Basal Cell Carcinoma Market Trends

      Table of Contents

      1

      Basal Cell Carcinoma Market Key Insights

      2

      Basal Cell Carcinoma Market Report Introduction

      3

      Executive Summary of BCC

      4

      Key Events

      5

      BCC Epidemiology and Market Forecast Methodology

      6

      BCC Market Overview at a Glance

      6.1

      Clinical Landscape Analysis (by Phase, RoA, and Molecule Type)

      6.2

      Market Share (%) Distribution of BCC by Therapies in 2024

      6.3

      Market Share (%) Distribution of BCC by Therapies in 2034

      7

      Disease Background and Overview: BCC

      7.1

      Introduction

      7.2

      Basal Cell Carcinoma Signs and Symptoms

      7.3

      Basal Cell Carcinoma Causes

      7.4

      Basal Cell Carcinoma Diagnosis

      8

      Basal Cell Carcinoma Treatment and Management

      8.1

      Treatment Guidelines and Recommendations (NCCN, ESMO)

      9

      Epidemiology and Patient Population of BCC in the 7MM

      9.1

      Key Findings

      9.2

      Assumptions and Rationale

      9.3

      Total Incident Cases of BCC in the 7MM

      9.4

      The United States

      9.4.1

       Total Incident Cases of Non-Melanoma Skin Cancer in the United States

      9.4.2

       Total Incident Cases of BCC in the United States

      9.4.3

       Subtype-specific Incident Cases of BCC in the United States

      9.4.2

       Stage-specific Incident Cases of BCC in the United States

      9.4.5

       Line-wise Treated Cases of BCC in the United States

      9.5

      EU4 and the UK

      9.6

      Japan

      10

      Basal Cell Carcinoma Patient Journey

      11

      Marketed Basal Cell Carcinoma Therapies

      11.1

      Key Competitors

      11.2

      Cemiplimab (LIBTAYO): Regeneron and Sanofi

      11.2.1

      Product Description

      11.2.2

      Regulatory Milestones

      11.2.3

      Other Developmental Activities

      11.2.4

      Summary of Pivotal Trials

      11.2.5

      Clinical Development

      11.2.5.1

      Clinical Trials Information

      11.2.6

      Safety and Efficacy

      11.2.7

      Analyst Views

      11.3

      Sonidegib (ODOMZO): Novartis

      List to be continued in the report…

      12

      Emerging Basal Cell Carcinoma Therapies

      12.1

      Key Competitors

      12.2

      LTX-315/VP-315: Lytix Biopharma/Verrica Pharmaceuticals

      12.2.1

      Product Description

      12.2.2

      Other Developmental Activities

      12.2.3

      Clinical Development

      12.2.3.1

      Clinical Trials Information

      12.2.4

      Safety and Efficacy

      12.2.5

      Analyst Views

      12.3

      SP-002: Stamford Pharmaceuticals

      List to be continued in the report…

      13

      BCC Market: 7MM Analysis

      13.1

      Key Findings

      13.2

      Key Basal Cell Carcinoma Market Forecast Assumptions

      13.3

      Basal Cell Carcinoma Market Outlook

      13.4

      Conjoint Analysis

      13.5

      Total Market Size of BCC in the 7MM

      13.6

      Total Market Size of BCC by Therapies in the 7MM

      13.7

      The United States Basal Cell Carcinoma Market Size

      13.7.1

      Total Market Size of BCC in the United States

      13.7.2.

      Market Size of BCC by Therapies in the United States

      13.8

      EU4 and the UK Basal Cell Carcinoma Market Size

      13.9

      Japan Basal Cell Carcinoma Market Size

      14

      KOL Views on Basal Cell Carcinoma 

      15

      Basal Cell Carcinoma Market SWOT Analysis

      16

      Basal Cell Carcinoma Market Unmet Needs

      17

      Basal Cell Carcinoma Market Access and Reimbursement

      17.1

      The United States

      17.2

      In EU4 and the UK

      17.3

      Japan

      17.4

      Summary and Comparison of Market Access and Pricing Policy Developments in 2025

      17.5

      Market Access and Reimbursement of BCC

      18

      Bibliography

      19

      Basal Cell Carcinoma Market Report Methodology

      Related Reports

      Basal Cell Carcinoma Clinical Trial Analysis

      Basal Cell Carcinoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key BCC companies, including PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, among others.

      Nevoid Basal Cell Carcinoma Syndrome Market

      Nevoid Basal Cell Carcinoma Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nevoid basal cell carcinoma syndrome companies, including Medicus Pharma Ltd., Sol-Gel Technologies, Jazz Pharmaceuticals, Ono Pharmaceuticals, Bristol Myers Squibb, Inhibitor Therapeutics, Genentech, Feldan Therapeutics Inc., Kintara Therapeutics Inc., Mayne Pharma Group Ltd., Palvella Therapeutics LLC, PellePharm Inc., among others.

      Nevoid Basal Cell Carcinoma Syndrome Pipeline

      Nevoid Basal Cell Carcinoma Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key BCC companies, including Medicus Pharma Ltd., Sol-Gel Technologies, Jazz Pharmaceuticals, Ono Pharmaceuticals, Bristol Myers Squibb, Inhibitor Therapeutics, Genentech, Feldan Therapeutics Inc., Kintara Therapeutics Inc., Mayne Pharma Group Ltd., Palvella Therapeutics LLC, PellePharm Inc., among others.

      Cutaneous Squamous Cell Carcinoma Market

      Cutaneous Squamous Cell Carcinoma Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key cutaneous squamous cell carcinoma companies, including Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur 

      [email protected] 

      +14699457679

      www.delveinsight.com

      Logo - https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.